These findings, together with clinical data showing that the adverse prognosis of IKZF1 deletion is mitigated by co-occurring ERG loss, position ERG as a key effector of IKAROS deficiency and a potential therapeutic vulnerability in IKZF1-mutated leukemias. This evidence concerns the gene ERG and leukemia.